Anchors “Adopt a District” initiative and becomes the first private hospital in North India to launch Drug Resistant Tuberculosis (DRTB) clinic
24th August 2022, Gurugram: With an aim to galvanize corporates in the state of Haryana to contribute to the National Tuberculosis Elimination Program (NTEP) and launch new initiatives under the aegis of Mission TB Free Haryana, Medanta, in association with The Union, under the guidance of NTEP Haryana, organized a multi-stakeholder event engaging corporates and government stakeholders. As part of the program, deliberation was held with potential and existing corporate partners from the state of Haryana, encouraging them to support the national initiative. Towards Vision 2025 – TB Free Haryana, Hon’ble Chief Minister of Haryana, Shri Manohar Lal Khattar Ji announced the “Adopt a District” initiative and inaugurated the Drug Resistant Tuberculosis (DRTB) clinic in Medanta Gurugram in the presence of Dr. Naresh Trehan (Chairman and Managing Director, Medanta), Dr. Anand Jaiswal (Senior Director) and Dr. Bornali Datta (Director) from the Department of Respiratory and Sleep Medicine, Medanta, Gurugram. The event was also graced by Dr. Kuldeep Singh Sachdeva (Director, Southeast Asia region, International Union Against Tuberculosis and Lung Diseases) and Dr. Rajesh Raju (State TB Officer).
The objective of “Adopt a District” initiative is to encourage each corporate to support at least one district of Haryana, allowing them to assist the state bridge the gap in TB care services. This will strengthen and support the robust NTEP that works to detect TB in the unscreened population and establish linkages between identified patients, and the government healthcare and treatment services.
The Drug Resistant Tuberculosis (DRTB) clinic in Medanta, Gurugram will operate in close collaboration with the Central, State and District Tuberculosis Divisions to enhance access to the most advanced TB therapy available in the country. TB treatment regimens are lengthy, making it difficult for patients to follow through. They also leave the treatment halfway because of lack of access to therapy, which puts them at risk of developing multi-drug resistant tuberculosis. The DRTB Clinic will provide patients with end-to-end clinical and infrastructural support, minimizing the gap between TB detection and treatment. It will offer TB screening, diagnosis, government-approved advanced treatment therapeutics, regular patient monitoring and follow-ups. The outcomes will be recorded and reported as per the government guideline.
Speaking on the occasion, Shri Khattar Ji, said, “We have made significant progress in strengthening the infrastructure for TB treatment in Haryana. However, we must recognize that to scale-up access to therapy, private-public partnerships and multi-stakeholder models are the way forward. Collaboration with Medanta and launch of ‘Adopt a District’ initiative is a step towards achieving the National Goal of TB elimination by 2025.”
Dr. Naresh Trehan, Chairman and Managing Director, Medanta, said, “Timely screening, detection and treatment play a crucial role in the prevention and management of Tuberculosis. Currently, a vast majority of patients go undetected and untreated in India, significantly increasing the disease burden. TB is a serious challenge that has been plaguing the nation. Launch of ‘Adopt a District’ initiative and the DRTB Clinic under the supervision of the Government reflects our commitment to eradicate TB from India with concerted, consistent efforts in this direction.”
We love to hear about our doctors, facilities
and your treatment at Medanta.
The User agrees and acknowledges that the User has read, understood and accepts the terms and conditions contained in the brochure provided with the Device (“Device”) with respect to its usage, operations, return / replacement and warranty policy.
The User hereby agrees and acknowledges that the Device (hardware and software) used in the provision
of services by Medanta is being provided on “as is” and “as available” basis through Alivecor India Private
Limited. Neither does Medanta endorse or promote the Device in any manner nor will Medanta be liable
for any claims, representations or warranties, whether express or implied as to the safety, reliability,
durability and performance of the device.
The services once availed cannot be cancelled except in cases where the User requests to cancel the service on the day of purchase in which case, full amount of service fees shall be refunded to the User provided that the Device has not been unboxed.
Before the expiry of service duration, the User can extend the services by availing various program options. For the said purposes, the User can call our helpline number +91 124 4141414 or visit www.medanta.org. The extended program availed by the User shall be activated automatically on expiry of existing program of services.
In cases where the User has opted for availing the Services through rented Device, a refundable deposit amount of ₹ 5,000 (“Deposit Amount”) shall be applicable and paid by the User. The refund of Deposit Amount shall be subject to return of the Device in working and undamaged condition. Refund of Deposit Amount shall be made through the same mode of payment as that of purchase in cases where the User personally visits the Medanta for returning the Device. If the User opts to return the Device through post, Deposit Amount shall be refunded electronically thorough NEFT or Bank transfer by Medanta within seven (7) working days of receipt of the Device and receipt of scanned image/copy of the ‘Cancelled Cheque’ of the User’s bank account.
Upon expiry of the services (either in terms of number of ECG or duration of the program) availed by the
User, the Device has to be returned within ten (10) days failing which the Deposit Amount shall be
Please note that the ECG pack or Refundable Device deposit are non-transferable from one patient to another.